Breakthrough study aims to spare rectal cancer patients from surgery
NCT ID NCT07483060
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a targeted chemoradiotherapy can completely eliminate early-stage rectal cancer, allowing patients to avoid surgery and keep their rectum. 90 adults with small, localized tumors will either receive standard surgery or the new treatment followed by close monitoring. The goal is to see if the cancer stays away for at least one year without needing an operation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- Digital nurse companion: could an app ease the burden of chronic illness?
- Which rectal cancer surgery preserves quality of life better? a study investigates
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- Can AI learn to grade endoscopy quality from video?
- Can precision protons spare rectal cancer patients from harsh side effects?